Caveolin-1 Expression and Hemodynamics in COPD Patients by Huber, Lars C et al.
  The Open Respiratory Medicine Journal, 2009, 3, 73-78 73 
 
  1874-3064/09   2009 Bentham Open 
Open Access 
Caveolin-1 Expression and Hemodynamics  
in COPD Patients 
Lars C. Huber
*,1,2, Alex Soltermann
3, Manuel Fischler
1, Steffen Gay
2,  
Walter Weder
4, Erich W. Russi
5, Rudolf Speich
1 and Silvia Ulrich
1 
1Working Group for Pulmonary Hypertension, Department for Internal Medicine, University Hospital Zurich, Zurich, 
Switzerland 
2Center for Experimental Rheumatology and Zurich Center for Integrative Human Physiology (ZIHP), University   
Zurich, Zurich, Switzerland 
3Institute for Surgical Pathology, University Hospital Zurich, Zurich, Switzerland 
4Division of Thoracic Surgery, Department for Surgery, University Hospital Zurich, Zurich, Switzerland 
5 Division of Pulmonology, Department for Internal Medicine, University Hospital Zurich, Zurich, Switzerland 
Abstract: Caveolin-1 is a regulator of both intracellular calcium homeostasis and endothelial nitric oxide synthase and 
may play a pathogenetic role in pulmonary hypertension. In the present study, we aimed to investigate the correlations 
between pulmonary hemodynamics and vessel morphology including the expression of Caveolin-1 in pulmonary 
arterioles from patients with chronic obstructive pulmonary disease (COPD) who underwent lung-volume reduction 
surgery. Staining and subsequent analysis was performed on paraffin-embedded lung tissue from COPD patients (n = 12). 
Pulmonary arteries with an external diameter of 100-500μm were analysed. Immunhistochemistry with antibodies against 
caveolin-1 was performed and intensity was assessed. Morphometric data were obtained by using computer-assisted 
imaging software. The findings were quantified and correlated to hemodynamic data obtained by right-heart 
catheterization. In COPD patients with pulmonary hypertension (n = 5), the expression of caveolin-1 within the medial 
smooth muscle cell layer was found to be increased, whereas the intimal caveolin-1 was more prominently expressed in 
COPD patients with normal pulmonary pressures (n = 7). The ratio between these expression patterns was positively 
correlated to the mean pulmonary artery pressure. Similar findings were observed for the ratio between intimal and medial 
thickness as well as for the expression of smooth muscle actin (SMA). 
Taken together, the expression of caveolin-1 within medial smooth muscle cells of pulmonary arteries in patients with 
COPD is associated with pulmonary hypertension. Our results thus emphasize a potential novel player in the pathogenesis 
of COPD-associated pulmonary hypertension. 
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BACKGROUND 
  Chronic obstructive pulmonary disease (COPD) is the 
fourth leading cause of death in industrialized countries [1]. 
One factor contributing to the devastating outcome of end-
stage COPD is the development of pulmonary hypertension 
and cor pulmonale. In cross-sectional studies, pulmonary 
hypertension and right heart failure have been found in more 
than 10% of patients dying from COPD [2, 3]. The arterial 
vessels in idiopathic pulmonary hypertension are 
characterized by intense thickening of their walls through 
fibromuscular proliferation and microthrombotic occlusion 
[4, 5], whereas in the setting of COPD, vasoconstriction 
induced by hypoxia may play a pivotal role. In either case, 
the molecular factors mediating the vascular changes that 
increase pulmonary vascular resistance in COPD patients 
remain largely unravelled so far. 
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  Recently, the role of caveolins (Cav) as emerging 
signalling molecule has been investigated in animal models 
of pulmonary hypertension as well as in lung tissue samples 
from patients with idiopathic pulmonary arterial 
hypertension [6-9]. Cav-1 is a 22kDa protein located in 
cholesterol- and glycosphingolipid enriched microdomains 
(lipid rafts or caveolae) that act as chaperons and scaffolding 
regions in order to anchor and regulate proteins [7, 10, 11]. 
In this regard, Cav-1 is involved in the regulation of many 
cellular processes including signal transduction and calcium 
homeostasis [12]. Moreover, a strong relationship between 
Cav-1 and endothelial nitric oxide-synthase (eNOS) has been 
described (reviewed in [13]) and binding of eNOS to Cav-1 
appears to inhibit the enzymatic function [14]. Both, changes 
in the intracellular calcium-storage resulting in increased 
vascular tone and a reduction in the production and release 
of endothelial NO, have been associated with the 
pathogenesis of pulmonary hypertension. The knockout of 
the cav-1 gene in mice resulted in lung fibrosis and 
subsequent development of cor pulmonale [9, 15]. 
Conversely, a recent study by Patel has found an increased 74    The Open Respiratory Medicine Journal, 2009, Volume 3  Huber et al. 
expression of Cav-1 in smooth muscle but not in endothelial 
cells in pulmonary arteries from patients with idiopathic 
pulmonary arterial hypertension [7]. 
  Along this line, we investigated the vessel morphology 
and expression of Cav-1 in small pulmonary arteries from 
COPD patients that underwent lung-volume reduction 
surgery (LVRS). 
METHODS AND MATERIALS 
Patients/Tissue Sections 
  Paraffin-embedded lung tissue sections were obtained 
from COPD patients undergoing lung volume reduction 
surgery or lung transplantation. Pulmonary hemodynamics 
was assessed by right-heart catheterization performed before 
surgery. Patients with a mean pulmonary arterial pressure 
(mPAP)   20mmHg were chosen as controls (n = 7), 
whereas patients with a mPAP  25mmHg were considered 
to have pulmonary hypertension (n = 5). The experimental 
use of these data was approved by an internal review board 
of the local Ethics committee of Zurich. In addition, all 
patients gave written informed consent for further 
experimental analysis of their explanted tissue and clinical 
data. Details of patients’ characteristics are provided in Table 
1. 
Immunohistochemistry 
  Serial sections of 2μm were manufactured from tissue 
blocks and were stained with hematoxylin eosin (HE) and 
Elastica van Gieson (EVG). Immunhistochemistry was 
performed on a Ventana automat (Ventana Medical Systems) 
with antibodies directed against Cav-1 (BD Transduction 
Laboratories, mouse monoclonal, clone 2297, 1: 100) and 
smooth muscle actin (-SMA) prior to analysis by light 
microscopy. For analysis, staining was assessed on 3 
vessels/slide in a semiquantitative manner by using a visual 
scoring system (0 = no staining, 1 = weak, 2 = moderate, 3 = 
strong). 
Morphometry 
  Morphometry data were obtained by using computer-
assisted imaging software (Axiovision, Zeiss). Pulmonary 
arteries with an external diameter of 100-500μm were 
randomly chosen followed by analysis (n = 7 per slide and 
individual patient). Only vessels with a cross-sectional 
morphology were chosen to minimize artificial effects by 
longitudinal or tangential cuts. Additionally, tissue shrinkage 
was corrected by calculation of a narrowing index. The 
adventitial layer, the external and internal elastic laminas 
(EEL and IEL, respectively) encompassing the vessel’s 
smooth muscle cell layer (medial layer) as well as the intimal 
layer were outlined manually at the screen. The perimeter 
and the corresponding diameter were calculated 
automatically by the imaging software. Moreover, the 
diameter was corrected by a narrowing index to avoid 
artificial vascular contraction due to tissue shrinkage [16]. 
Thus, the measured perimeter was divided by  to calculate a 
theoretical diameter of a fully extended vessel. Lumen as 
well as intimal, medial and adventitial layer areas were 
calculated and expressed as percentage of the whole vessel 
area. The final data per patient was expressed as mean of all 
vessels analysed. 
Statistics 
  For statistical analysis, the unpaired t-test was used to 
compare data from the two groups. Correlation analyses 
(correlation coefficient Pearson r) were performed to assess 
correlations between pulmonary hemodynamics, thickness of 
vessel layers and immunohistochemical expression of 
distinct proteins. Statistics were performed using GraphPad 
Prism Software system (GraphPad Software, San Diego, CA, 
USA) and a p value <0.05 was considered to be statistically 
significant. All data are shown as mean ± SD. 
RESULTS 
Vessel Morphometry 
  As shown in Table 2, a total of 7 vessels were 
investigated for each individual patient with similar mean 
diameters of 223.1 ± 85.9 μm for COPD patients with 
pulmonary hypertension and of 292 ± 88 μm for COPD 
patients without pulmonary hypertension, respectively. The 
intimal layer area was found to be strongly reduced from 
40.8 ± 16.8% in patients without pulmonary hypertension to 
31.7 ± 16.3% in patients with pulmonary hypertension. No 
significant changes have been observed in the thickness of 
the smooth muscle cell area between the two groups. The 
Table 1.  Characteristics of Analysed Patients 
 
  COPD with PH (n = 5)  COPD without PH (n = 7) 
age  56 ± 11.9 [42-72]  67 ± 9.0 [54-79] 
gender (m: f)  2: 3  4: 3 
ethnic group  Caucasian Caucasian 
mPAP (mmHg)  29.6 ± 5.1 [38-26]  16.7 ± 2.7 [20-12] 
spirometric data 
- FVC (% predicted) 
- FEV1 (% predicted) 
 
59 ± 19.8 
26 ± 7.3 
 
59 ± 12.9 
27 ± 5.8 
SaO2 (%)  89 ± 5.2  94 ± 3.9 
smoking status 
- pack years 
5/5 
62 ± 53.1 [10-150] 
7/7 
61 ± 22.3 [35-100] 
Abbreviations used: FVC forced vital capacity, FEV1 forced expiratory volume in one second, SaO2 oxygen saturation in arterial blood. Caveolin-1 and Pulmonary Hemodynamics in COPD  The Open Respiratory Medicine Journal, 2009, Volume 3    75 
thickness of the adventitial area on the other hand, was 
significantly increased in patients with pulmonary 
hypertension from 27 ± 19% to 40.4 ± 16.4%, respectively (p 
= 0.05). 
  When analysed by subsequent linear regression analysis 
(Fig. 1), the ratio between the intimal and the medial vessel 
layer was positively correlated to the mean pulmonary 
arterial pressure (r
2 = 0.49). Similarly, the thickness of the 
adventitial layer expressed as percentage of the whole vessel 
was strongly correlated to the mPAP (r
2 = 0.67). 
Caveolin-1 Expression 
  By using a visual scoring system, immunohistochemical 
stainings of pulmonary arteries were assessed in a 
semiquantitative manner (Fig. 2). The expression of Cav-1 
within the smooth muscle cell layer was found to be 
increased in COPD patients with pulmonary hypertension as 
compared to the individuals without pulmonary hypertension 
(1.78 ± 0.73 versus 1.29 ± 0.5). On the other hand, the 
intimal Cav-1 was most prominently expressed in COPD 
patients without pulmonary hypertension (2.6 ± 0.37), but 
appeared to be reduced in patients with pulmonary 
hypertension (2.34 ± 0.52). Fig. (3) shows representative 
images of the Cav-1 expression pattern in pulmonary arteries 
of COPD patients with and without pulmonary hypertension. 
  Subsequent correlation analysis found a strong positive 
association between the mPAP and the Cav-1 expression 
pattern when expressed as ratio between medial and intimal 
Cav-1 (r
2 = 0.53, p = 0.007) as shown in Fig. (1b). A similar 
relationship was detected between the expression of -SMA 
in the intimal and medial layer and the corresponding mPAP 
(Fig. 1c). 
DISCUSSION 
  Caveolins have emerged as novel signalling molecules 
acting as signal transducers and mediators of calcium 
homeostasis. The isoform Cav-1 has been particularly 
investigated in animal models of pulmonary hypertension 
and, by one pilot study, in human tissue samples derived 
from patients with idiopathic pulmonary arterial 
hypertension [6-9]. 
  Our investigation of the vessel morphometry and the 
Cav-1 expression in small pulmonary arteries derived from 
COPD patients with and without concomitant pulmonary 
hypertension showed a reduction of the Cav-1 expression in 
the intimal layer of the vessels in patients with pulmonary 
hypertension. Conversely, the Cav-1 expression in the 
smooth muscle cell layer was found to be increased in COPD 
patients with pulmonary hypertension. The ratio of either 
trend, assessed in a semiquantatitive manner at the light 
microscopy, was associated with rising pulmonary arterial 
pressure. Since similar changes were also observed in the 
expression pattern of an independent smooth muscle cell 
marker (i.e. -SMA), it might be suggested that the Cav-1 
expression is strongly linked to the vascular distribution of 
smooth muscle cells. 
  In pulmonary hypertension, the weak expression of Cav-
1 in the intimal layer might be due to an accelerated loss of 
caveolar peptides through a disrupted and dysfunctional 
endothelium. Since the bone morphogenetic protein receptor 
type II (BMPR2), one of the pathogenetic key molecules 
involved in the development of pulmonary hypertension, co-
localizes with caveolins [17], the loss of Cav-1 might also be 
explained by the downregulation of the BMPR2 at the 
endothelial surface of pulmonary arteries as it has been 
described repeatedly in pulmonary hypertension. The 
elevated vascular resistance in pulmonary hypertension is 
mediated by calcium ions that promote the contraction of 
smooth muscle cells on the molecular level. The weak 
expression of Cav-1 in the intimal area of pulmonary arteries 
thus could alternatively be explained by an enhanced 
transcytosis of calcium by [Ca
2+]-influx channels and ion 
pumps located on caveolar domains through the endothelium 
to the smooth muscle cell layer. Conversely, the high 
Table 2.  Vessel Morphometry 
 
  COPD with PH (n = 5)  COPD without PH (n = 7) 
vessels analysed/ slide  7 7 
diameter of pulmonary artery (μm)
¶  223.1 ± 85.9 [110-419]  292 ± 88 [125-465] 
diameter of EEL (μm) 
¶  193.6 ± 83.6  265.6 ± 80.6 
diameter of IEL (μm) 
¶  169.8 ± 75.4  233.3 ± 76.6 
intimal area (mm
2) 
-  % of total vessel area 
10.0 ± 10.7 
31.7 ± 16.3 
16.4 ± 13.5 
40.8 ± 16.8 
media area (mm
2) 
-  % of total vessel area 
7.9 ± 6.9 
27.3 ± 11.1 
13.1 ± 12.2 
32.1 ± 17.6 
adventitial area (mm
2) 
-  % of total vessel area 
10.0 ± 6.6 
40.4 ± 16.4 
12.6 ± 13.2 
27 ± 19 
Caveolin expression 
-  intimal caveolin 
-  medial caveolin 
 
2.34 ± 0.52 
1.78 ± 0.73 
 
2.60 ± 0.37 
1.29 ± 0.5 
¶ Narrowing index applied. 
Theoretical diameter was calculated by dividing the measured perimeter by . 
EEL = external elastic layer. 
IEL = internal elastic layer. 76    The Open Respiratory Medicine Journal, 2009, Volume 3  Huber et al. 
expression of Cav-1 observed within the vascular smooth 
muscle cells in COPD patients with pulmonary hypertension 
is probably related to increased levels of sarcoplasmic [Ca
2+] 
due to highly active transient receptor potential channels. It 
is unclear at the moment, whether the abundant expression of 
Cav-1 within vascular smooth muscle cells is directly 
connected to the upregulation of other important signalling 
molecules in COPD patients with pulmonary hypertension. 
However, several molecules with pathogenetic relevance for 
the development of pulmonary hypertension have been 
located on caveolins including epidermal growth factor 
(EGF), platelet-derived growth factor (PDGF), receptors for 
endothelin and serotonine transporters [8, 18-23]. Our data 
thus support the hypothesis that caveolins are involved in the 
regulation and expression of these factors and, in turn, are of 
pathogenetic importance for the development of pulmonary 
hypertension. 
  The clinical relevance of our findings, on the other hand, 
is less clear and has to be addressed by further studies. Since 
novel therapies directed against some of the molecules 
mentioned above have already been approved for the 
treatment of pulmonary hypertension, or, at least, are 
currently under investigation in clinical trials, we believe 
that caveolins might offer an interesting molecular target for 
novel therapeutic strategies as well. Along this line, HMG-
CoA-reductase inhibitors (statins) were shown to alter the 
 
Fig. (1). Correlation analyses. (A) Parametric analyses to calculate the Pearson r correlation coefficient showed strong associations between 
pulmonary hemodynamics (mPAP) and the ratio between the thickness of medial and intimal vessel areas (r
2 = 0.49). (B) Significant 
correlation were also found between mPAP and the ratio between medial : intimal Cav-1 expression (r
2 = 0.53, p = 0.007). (C) A similar 
correlation was found between mPAP and the ratio between medial : intimal -SMA expression (r
2 = 0.48). 
Fig. (2). Cross-sectional imaging studies of a pulmonary artery (IHC). Serial stainings performed at lung tissue slides derived from an 
index patient without pulmonary hypertension: (A) Hematoxylin-Eosin (HE) and (B) Elastin-van Gieson (EVG). 
mPAP
mPAP
m
e
d
i
a
l
:
i
n
t
i
m
a
l
 
a
r
e
a
C
a
v
-
1
 
e
x
p
r
e
s
s
i
o
n
 
(
m
e
d
i
a
l
:
i
n
t
i
m
a
l
)
A
B
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
10 15 20 25 30 35 40
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
10 15 20 25 30 35 40
0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
10 15 20 25 30 35 40
α
-
S
M
A
 
e
x
p
r
e
s
s
i
o
n
 
(
m
e
d
i
a
l
:
i
n
t
i
m
a
l
)
mPAP
C
A BCaveolin-1 and Pulmonary Hemodynamics in COPD  The Open Respiratory Medicine Journal, 2009, Volume 3    77 
distribution pattern of the cholesterol-enriched caveolins [7] 
and their application has been shown to ameliorate 
pulmonary hypertension in several animal models [24, 25]. 
  The “classical” morphological features of pulmonary 
hypertension such as the formation of a neo-intima and 
marked hyperproliferation of the smooth muscle cell layer 
have not been observed in the present study. This might be 
due to the fact that the increase in pulmonary vascular 
resistance in COPD-related pulmonary hypertension is 
generally very moderate. Our study is further limited by the 
lack of a control group consisting of patients without COPD 
and the relatively small number of patients. Nevertheless, the 
findings presented herein are in line with the data from Patel 
et al, and therefore strongly suggest a common molecular 
pathway involving caveolar proteins in the development of 
pulmonary hypertension both in its idiopathic form and in 
relation with advanced COPD. 
  In summary, we show for the first time that the 
expression pattern of Cav-1 within pulmonary arteries is 
associated with pulmonary hypertension in COPD patients. 
Consistent with the results from studies performed in tissue 
samples derived from idiopathic pulmonary arterial 
hypertension, the expression of Cav-1 was found to be 
correlated with the pulmonary arterial pressure. Since 
caveolin has been associated with different molecular players 
in pulmonary hypertension and, moreover, appears to 
regulate fibrosis a least in part, our results emphasize a 
potential novel factor in the pathogenesis of COPD-
associated pulmonary hypertension. 
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